<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928888</url>
  </required_header>
  <id_info>
    <org_study_id>11201</org_study_id>
    <nct_id>NCT01928888</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes</brief_title>
  <official_title>A Randomized, Double-blind, Three-fold Cross-over, Multi-center Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid (1000 mg Hydrotalcite), a Single Dose of Oral Famotidine 10 mg, and a Single Dose of Placebo in Patients With Acute Heartburn Episodes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of a single oral
      administration of 1000 mg Talcid® (study medication), a single oral administration of 10 mg
      famotidine and a single oral administration of placebo (comparator without an active
      substance) in treating the symptoms of acute heartburn episodes. The study is designed to
      collect more efficacy data on Talcid® in patients using self-medication to relief the
      symptoms of acute heartburn.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total heartburn relief over 0-60 min</measure>
    <time_frame>up to 60 minutes</time_frame>
    <description>The total heartburn relief is claculated as sum of the heartburn relief scores based on a 5-point verbal rating scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total heartburn relief 0-30 min after comparison hydrotalcite vs. placebo and vs famotidine</measure>
    <time_frame>up to 30 min</time_frame>
    <description>The total heartburn relief is claculated as sum of the heartburn relief scores based on a 5-point verbal rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total heartburn relief 0-3 h after comparison hydrotalcite vs. placebo and vs famotidine</measure>
    <time_frame>up to 3 h</time_frame>
    <description>The total heartburn relief is claculated as sum of the heartburn relief scores based on a 5-point verbal rating scale.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">559</enrollment>
  <condition>Heartburn</condition>
  <arm_group>
    <arm_group_label>Arm HFP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm HPF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm FHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm FPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm PHF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm PFH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talcid (Hydrotalcite, BAY4516H)</intervention_name>
    <description>2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine</description>
    <arm_group_label>Arm HFP</arm_group_label>
    <arm_group_label>Arm HPF</arm_group_label>
    <arm_group_label>Arm FHP</arm_group_label>
    <arm_group_label>Arm FPH</arm_group_label>
    <arm_group_label>Arm PHF</arm_group_label>
    <arm_group_label>Arm PFH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg</description>
    <arm_group_label>Arm HFP</arm_group_label>
    <arm_group_label>Arm HPF</arm_group_label>
    <arm_group_label>Arm FHP</arm_group_label>
    <arm_group_label>Arm FPH</arm_group_label>
    <arm_group_label>Arm PHF</arm_group_label>
    <arm_group_label>Arm PFH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine</description>
    <arm_group_label>Arm HFP</arm_group_label>
    <arm_group_label>Arm HPF</arm_group_label>
    <arm_group_label>Arm FHP</arm_group_label>
    <arm_group_label>Arm FPH</arm_group_label>
    <arm_group_label>Arm PHF</arm_group_label>
    <arm_group_label>Arm PFH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the age of 18 to 65 years

          -  A minimum of 6 months history of heartburn

          -  History of relief of heartburn episodes after self-medication (OTC use) within at
             least 2 hours

          -  Occurrence of heartburn episodes at least twice a week during the previous two months

          -  Severity of heartburn episodes at least 5 on an 11-category heartburn severity scale

        Exclusion Criteria:

          -  History of 'alarming symptoms' e.g. weight loss, vomiting, dysphagia, anemia,
             hematemesis or melaena

          -  History of gastric ulcer or gastroesophageal reflux disease requiring regular or
             intermittent therapy with H2-antagonists or proton pump inhibitors within the previous
             year

          -  History of significant gastrointestinal hemorrhage or gastrointestinal surgery

          -  Gastrointestinal odynophagia (pain during swallowing)

          -  History or concurrent known duodenitis, pyloric dysfunction with alkaline reflux,
             motility disturbances, Heliobacter pylori gastritis, or cholelithiasis

          -  Pregnant or lactating women, or sexually active women of child-bearing potential
             unless using effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ask Central Contact</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute heartburn episodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>Hydrotalcite</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

